Ocugen

With no FDA approved treatment for Stargardt disease, a rare, inherited retinal disorder affecting over 100,000 individuals across the U.S. and Europe, Ocugen’s OCU410ST modifier gene therapy is showing promising early safety and efficacy results.   Hear from Lejla Vajzovic, MD, FASRS, Director of the Duke Surgical Vitreoretinal Fellowship Program, Professor at Duke Eye Center, and Chair of Ocugen’s Retina Scientific Advisory Board, as she shares expert insights into the early clinical outcomes observed in patients treated with OCU410ST and what this could mean for the future of retinal disease therapy. Follow Ocugen and be part of something groundbreaking in gene therapy research. #OCU410ST #StargardtDisease #GeneTherapy #RareDisease #VisionResearch

Join us as we share how Ocugen is redefining the future of vision through our first-in-class, breakthrough modifier gene therapy platform. Ocugen Chairman, CEO, and Co-Founder, Shankar Musunuri, PhD, MBA, will participate in a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on Tuesday, May 26, 2026, from 10:30 to 10:55 a.m. EDT.   Watch the live webcast here: https://bit.ly/4wETPVB  A replay will be available for 30 days following the event. Additional information can be found in the Investors section of our website: https://ir.ocugen.com/ Stifel Financial Corp. #Ocugen #Biotech #GeneTherapy #Ophthalmology #RetinalDiseases #InvestorRelations

What is Stargardt disease? Stargardt disease is a rare inherited eye condition that leads to progressive central vision loss, often beginning early in life, and currently has no FDA-approved treatments. Ocugen’s investigational gene therapy candidate, OCU410ST, is designed to regulate pathways involved in the progression of Stargardt disease, offering potential hope for future treatment Like and share this post to help raise awareness for Stargardt disease and inherited retinal diseases. #StargardtDisease #GeneTherapy #OCU410ST #Biotech

Momentum continues at Ocugen with a major milestone! With $130.0 million in financing secured, we are well-positioned to advance our three late-stage programs and continue working toward our goal of filing three BLAs by 2028. Read how this financing milestone strengthens our path forward: https://bit.ly/4wrB1Jm   #GeneTherapy #Biotech #FinancialUpdate

Today, Shankar Musunuri, PhD, MBA, Chairman, CEO, and Co-founder of Ocugen, joined leading voices in biotech and ophthalmology at Retina World Congress during the panel on inherited and rare retinal diseases.   Dr. Musunuri shared how Ocugen is advancing potentially one-time gene therapies for severe blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy (GA). He also highlighted OCU410, a first-in-class, RORA-based modifier gene therapy designed to support retinal integrity and potentially establish a new standard of care for patients with GA, as well as Ocugen’s goal of three BLA filings by 2028.   #RetinaWorldCongress #GeneTherapy #GeographicAtrophy #StargardtDisease #RetinitisPigmentosa

Last week at the ARVO Annual Meeting, Ocugen was proud to be part of important conversations advancing retinal disease research and innovation. Murthy Chavali, Ph.D., Director of Clinical Development, shared a poster presentation on behalf of Ocugen: “Reducing Variability in Autofluorescence Measurements Through Automation.” The study in Stargardt disease evaluated definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence (QDAF) using the Strauss method, the Extended Strauss (A1) algorithm, and a convolutional neural network (CNN), with potential relevance to geographic atrophy. We’re honored to collaborate and connect with the ophthalmology community as we continue working to make a meaningful difference for patients affected by blindness diseases. Association for Research in Vision and Ophthalmology (ARVO) #GeographicAtrophy #StargardtDisease #Ophthalmology #Biotech #ARVO2026

ICYMI: Ocugen’s first quarter 2026 financial results, announced this morning by Chairman, CEO, and Co-founder Shankar Musunuri, PhD, MBA, and the leadership team, highlight strong momentum: • Cash runway extended into 2028 • Positive OCU410 Phase 2 data (31% lesion reduction) • Enrollment complete for OCU400 and OCU410ST registration trials • Advancing toward BLA submissions We’re focused on transformative one-time treatment for blindness diseases. Read more: bit.ly/4tS7XJv #EarningsUpdate #InvestorUpdate #ClinicalTrials #Ocugen #GeneTherapy

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function. If you found this helpful, share it with someone who should know more about EZ.   #EyeHealth #Retina #MedicalInnovation #Ophthalmology #AMD #StargardtDisease

You won’t want to miss our quarterly update. On Tuesday, May 5, 2026 at 8:30 a.m. EDT, we will discuss the Company’s first quarter 2026 financial results and share business updates—hitting key milestones, while actively positioning the pipeline for upcoming catalysts. For more information on how to join, read our latest press release: https://bit.ly/4w6c9H5 A replay of the call and archived webcast will be available on the Ocugen Investor site: https://ir.ocugen.com/ #SaveTheDate #QuarterlyUpdate #Biotech

Ocugen leadership is taking the global stage this month. On Tuesday, April 28, 2026, Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-founder, and Abhishek Gupta, MBA, Executive Vice President, Commercial and Business Development, will present at leading biotech conferences in Puerto Rico and Rome, respectively. They will share updates on our gene therapy platform and progress toward commercialization. We look forward to connecting with investors and potential partners. Learn more in our latest press release: https://bit.ly/4e5oKnd Oppenheimer & Co. Inc. Alliance for Regenerative Medicine #Ocugen #Biotech #GeneTherapy #HealthcareInnovation